Skip to main content
Top
Published in: BMC Infectious Diseases 1/2007

Open Access 01-12-2007 | Research article

Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions

Authors: Hans P Duerr, Stefan O Brockmann, Isolde Piechotowski, Markus Schwehm, Martin Eichner

Published in: BMC Infectious Diseases | Issue 1/2007

Login to get access

Abstract

Background

Influenza pandemic preparedness plans are currently developed and refined on national and international levels. Much attention has been given to the administration of antiviral drugs, but contact reduction can also be an effective part of mitigation strategies and has the advantage to be not limited per se. The effectiveness of these interventions depends on various factors which must be explored by sensitivity analyses, based on mathematical models.

Methods

We use the freely available planning tool InfluSim to investigate how pharmaceutical and non-pharmaceutical interventions can mitigate an influenza pandemic. In particular, we examine how intervention schedules, restricted stockpiles and contact reduction (social distancing measures and isolation of cases) determine the course of a pandemic wave and the success of interventions.

Results

A timely application of antiviral drugs combined with a quick implementation of contact reduction measures is required to substantially protract the peak of the epidemic and reduce its height. Delays in the initiation of antiviral treatment (e.g. because of parsimonious use of a limited stockpile) result in much more pessimistic outcomes and can even lead to the paradoxical effect that the stockpile is depleted earlier compared to early distribution of antiviral drugs.

Conclusion

Pharmaceutical and non-pharmaceutical measures should not be used exclusively. The protraction of the pandemic wave is essential to win time while waiting for vaccine development and production. However, it is the height of the peak of an epidemic which can easily overtax general practitioners, hospitals or even whole public health systems, causing bottlenecks in basic and emergency medical care.
Appendix
Available only for authorised users
Literature
2.
go back to reference Mounier-Jack S, Coker RJ: How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet. 2006, 367: 1405-1411. 10.1016/S0140-6736(06)68511-5.CrossRefPubMed Mounier-Jack S, Coker RJ: How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet. 2006, 367: 1405-1411. 10.1016/S0140-6736(06)68511-5.CrossRefPubMed
3.
go back to reference Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L: Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006, 163: 181-187. 10.1093/aje/kwj024.CrossRefPubMed Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L: Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006, 163: 181-187. 10.1093/aje/kwj024.CrossRefPubMed
4.
go back to reference Webby RJ, Webster RG: Are we ready for pandemic influenza?. Science. 2003, 302: 1519-1522. 10.1126/science.1090350.CrossRefPubMed Webby RJ, Webster RG: Are we ready for pandemic influenza?. Science. 2003, 302: 1519-1522. 10.1126/science.1090350.CrossRefPubMed
5.
go back to reference Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S: Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005, 11: 1355-1362.CrossRefPubMedPubMedCentral Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S: Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005, 11: 1355-1362.CrossRefPubMedPubMedCentral
6.
go back to reference Longini IM, Halloran ME, Nizam A, Yang Y: Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004, 159: 623-633. 10.1093/aje/kwh092.CrossRefPubMed Longini IM, Halloran ME, Nizam A, Yang Y: Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004, 159: 623-633. 10.1093/aje/kwh092.CrossRefPubMed
7.
go back to reference Bell DM: Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006, 12: 81-87.CrossRefPubMed Bell DM: Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006, 12: 81-87.CrossRefPubMed
8.
go back to reference Bell DM: Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006, 12: 88-94.CrossRefPubMed Bell DM: Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006, 12: 88-94.CrossRefPubMed
9.
go back to reference Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005, 437: 209-214. 10.1038/nature04017.CrossRefPubMed Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005, 437: 209-214. 10.1038/nature04017.CrossRefPubMed
10.
go back to reference Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS: Strategies for mitigating an influenza pandemic. Nature. 2006, 442: 448-452. 10.1038/nature04795.CrossRefPubMed Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS: Strategies for mitigating an influenza pandemic. Nature. 2006, 442: 448-452. 10.1038/nature04795.CrossRefPubMed
11.
go back to reference Germann TC, Kadau K, Longini IM, Macken CA: Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A. 2006, 103: 5935-5940. 10.1073/pnas.0601266103.CrossRefPubMedPubMedCentral Germann TC, Kadau K, Longini IM, Macken CA: Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A. 2006, 103: 5935-5940. 10.1073/pnas.0601266103.CrossRefPubMedPubMedCentral
12.
go back to reference Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME: Containing pandemic influenza at the source. Science. 2005, 309: 1083-1087. 10.1126/science.1115717.CrossRefPubMed Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME: Containing pandemic influenza at the source. Science. 2005, 309: 1083-1087. 10.1126/science.1115717.CrossRefPubMed
13.
go back to reference Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A: Antivirals for influenza in healthy adults: systematic review. Lancet. 2006, 367: 303-313. 10.1016/S0140-6736(06)67970-1.CrossRefPubMed Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A: Antivirals for influenza in healthy adults: systematic review. Lancet. 2006, 367: 303-313. 10.1016/S0140-6736(06)67970-1.CrossRefPubMed
14.
go back to reference Eichner M: Case isolation and contact tracing can prevent the spread of smallpox. Am J Epidemiol. 2003, 158: 118-128. 10.1093/aje/kwg104.CrossRefPubMed Eichner M: Case isolation and contact tracing can prevent the spread of smallpox. Am J Epidemiol. 2003, 158: 118-128. 10.1093/aje/kwg104.CrossRefPubMed
15.
go back to reference Eichner M, Schwehm M, Duerr HP, Brockmann SO: The influenza pandemic preparedness planning tool InfluSim. BMC Infect Dis. 2007, 7: 17-10.1186/1471-2334-7-17.CrossRefPubMedPubMedCentral Eichner M, Schwehm M, Duerr HP, Brockmann SO: The influenza pandemic preparedness planning tool InfluSim. BMC Infect Dis. 2007, 7: 17-10.1186/1471-2334-7-17.CrossRefPubMedPubMedCentral
17.
go back to reference Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003, 163: 1667-1672. 10.1001/archinte.163.14.1667.CrossRefPubMed Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003, 163: 1667-1672. 10.1001/archinte.163.14.1667.CrossRefPubMed
18.
go back to reference Shortridge KF: Influenza pandemic preparedness: gauging from EU plans. Lancet. 2006, 367: 1374-1375. 10.1016/S0140-6736(06)68512-7.CrossRefPubMed Shortridge KF: Influenza pandemic preparedness: gauging from EU plans. Lancet. 2006, 367: 1374-1375. 10.1016/S0140-6736(06)68512-7.CrossRefPubMed
19.
go back to reference Frost WH: The epidemiology of influenza. JAMA : the journal of the American Medical Association. 1919, 73: 313-318.CrossRef Frost WH: The epidemiology of influenza. JAMA : the journal of the American Medical Association. 1919, 73: 313-318.CrossRef
20.
go back to reference Collins SD: The influenza epidemic of 1928-1929 with comparative data for 1918-1919. American journal of public health and the nation's health. 1930, 12: 119-129.CrossRef Collins SD: The influenza epidemic of 1928-1929 with comparative data for 1918-1919. American journal of public health and the nation's health. 1930, 12: 119-129.CrossRef
21.
go back to reference Mills CE, Robins JM, Lipsitch M: Transmissibility of 1918 pandemic influenza. Nature. 2004, 432: 904-906. 10.1038/nature03063.CrossRefPubMed Mills CE, Robins JM, Lipsitch M: Transmissibility of 1918 pandemic influenza. Nature. 2004, 432: 904-906. 10.1038/nature03063.CrossRefPubMed
23.
go back to reference Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE: Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998, 101: 643-649.CrossRefPubMedPubMedCentral Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE: Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998, 101: 643-649.CrossRefPubMedPubMedCentral
24.
go back to reference Fraser C, Riley S, Anderson RM, Ferguson NM: Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004, 101: 6146-6151. 10.1073/pnas.0307506101.CrossRefPubMedPubMedCentral Fraser C, Riley S, Anderson RM, Ferguson NM: Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004, 101: 6146-6151. 10.1073/pnas.0307506101.CrossRefPubMedPubMedCentral
25.
go back to reference Arino J, Brauer F, van den Driessche P, Watmough J, Wu J: Simple models for containment of a pandemic. Journal of the Royal Society Interface. 2006, 3: 453–457-10.1098/rsif.2006.0112.CrossRefPubMedCentral Arino J, Brauer F, van den Driessche P, Watmough J, Wu J: Simple models for containment of a pandemic. Journal of the Royal Society Interface. 2006, 3: 453–457-10.1098/rsif.2006.0112.CrossRefPubMedCentral
26.
go back to reference Wallinga J, Teunis P: Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004, 160: 509-516. 10.1093/aje/kwh255.CrossRefPubMed Wallinga J, Teunis P: Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004, 160: 509-516. 10.1093/aje/kwh255.CrossRefPubMed
27.
go back to reference Nishiura H, Kuratsuji T, Quy T, Phi NC, Van Ban V, Ha LE, Long HT, Yanai H, Keicho N, Kirikae T, Sasazuki T, Anderson RM: Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam. Am J Trop Med Hyg. 2005, 73: 17-25.PubMed Nishiura H, Kuratsuji T, Quy T, Phi NC, Van Ban V, Ha LE, Long HT, Yanai H, Keicho N, Kirikae T, Sasazuki T, Anderson RM: Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam. Am J Trop Med Hyg. 2005, 73: 17-25.PubMed
28.
go back to reference Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, Zhu Z, Liang W, Chin DP, Schuchat A: Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerg Infect Dis. 2004, 10: 210-216.CrossRefPubMedPubMedCentral Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, Zhu Z, Liang W, Chin DP, Schuchat A: Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerg Infect Dis. 2004, 10: 210-216.CrossRefPubMedPubMedCentral
30.
go back to reference Pourbohloul B, Meyers LA, Skowronski DM, Krajden M, Patrick DM, Brunham RC: Modeling control strategies of respiratory pathogens. Emerging Infectious Diseases. 2005, 11: 1249-1256.CrossRefPubMedPubMedCentral Pourbohloul B, Meyers LA, Skowronski DM, Krajden M, Patrick DM, Brunham RC: Modeling control strategies of respiratory pathogens. Emerging Infectious Diseases. 2005, 11: 1249-1256.CrossRefPubMedPubMedCentral
Metadata
Title
Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions
Authors
Hans P Duerr
Stefan O Brockmann
Isolde Piechotowski
Markus Schwehm
Martin Eichner
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2007
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-7-76

Other articles of this Issue 1/2007

BMC Infectious Diseases 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.